These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 22634298)
1. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Wang C; Zhuang Y; Zhang Y; Luo Z; Gao N; Li P; Pan H; Cai L; Ma Y Vaccine; 2012 Jul; 30(32):4790-9. PubMed ID: 22634298 [TBL] [Abstract][Full Text] [Related]
3. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605 [TBL] [Abstract][Full Text] [Related]
4. A novel liposomal recombinant lipoimmunogen enhances anti-tumor immunity. Shen KY; Liu HY; Li HJ; Wu CC; Liou GG; Chang YC; Leng CH; Liu SJ J Control Release; 2016 Jul; 233():57-63. PubMed ID: 27164542 [TBL] [Abstract][Full Text] [Related]
5. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Vasievich EA; Chen W; Huang L Cancer Immunol Immunother; 2011 May; 60(5):629-38. PubMed ID: 21267720 [TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. Yan W; Chen W; Huang L J Control Release; 2008 Aug; 130(1):22-8. PubMed ID: 18554742 [TBL] [Abstract][Full Text] [Related]
7. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377 [TBL] [Abstract][Full Text] [Related]
8. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Chen W; Yan W; Huang L Cancer Immunol Immunother; 2008 Apr; 57(4):517-30. PubMed ID: 17724588 [TBL] [Abstract][Full Text] [Related]
9. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion. Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347 [TBL] [Abstract][Full Text] [Related]
10. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells. Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Yan W; Chen W; Huang L Mol Immunol; 2007 Jul; 44(15):3672-81. PubMed ID: 17521728 [TBL] [Abstract][Full Text] [Related]
12. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Chen W; Huang L Mol Pharm; 2008; 5(3):464-71. PubMed ID: 18266319 [TBL] [Abstract][Full Text] [Related]
13. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma. Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135 [TBL] [Abstract][Full Text] [Related]
14. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Yan W; Huang L Int J Pharm; 2009 Feb; 368(1-2):56-62. PubMed ID: 18992312 [TBL] [Abstract][Full Text] [Related]
15. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution. Zhuang Y; Ma Y; Wang C; Hai L; Yan C; Zhang Y; Liu F; Cai L J Control Release; 2012 Apr; 159(1):135-42. PubMed ID: 22226776 [TBL] [Abstract][Full Text] [Related]
16. Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. Gandhapudi SK; Ward M; Bush JPC; Bedu-Addo F; Conn G; Woodward JG J Immunol; 2019 Jun; 202(12):3524-3536. PubMed ID: 31053626 [TBL] [Abstract][Full Text] [Related]
17. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy. Takeda Y; Azuma M; Matsumoto M; Seya T J Exp Clin Cancer Res; 2016 Sep; 35(1):143. PubMed ID: 27619885 [TBL] [Abstract][Full Text] [Related]
18. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
19. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Fujimoto C; Nakagawa Y; Ohara K; Takahashi H Int Immunol; 2004 Jan; 16(1):55-63. PubMed ID: 14688061 [TBL] [Abstract][Full Text] [Related]
20. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Hafner AM; Corthésy B; Merkle HP Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]